PubMed

Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial.

Keech A, Colquhoun D, Best J, Kirby A, Simes RJ, Hunt D, Hague W, Beller E, Arulchelvam M, Baker J, Tonkin A; LIPID Study Group.

Diabetes Care. 2003 Oct;26(10):2713-21.PMID: 14514569 [PubMed - indexed for MEDLINE]Related articlesFree article

Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators.

Goldberg RB, Mellies MJ, Sacks FM, Moyé LA, Howard BV, Howard WJ, Davis BR, Cole TG, Pfeffer MA, Braunwald E.

Circulation. 1998 Dec 8;98(23):2513-9.PMID: 9843456 [PubMed - indexed for MEDLINE]Related articlesFree article

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group.

[No authors listed]

N Engl J Med. 1998 Nov 5;339(19):1349-57.PMID: 9841303 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study.

Hague W, Forder P, Simes J, Hunt D, Tonkin A; LIPID Investigators.

Am Heart J. 2003 Apr;145(4):643-51.PMID: 12679760 [PubMed - indexed for MEDLINE]Related articles

Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up.

LIPID Study Group (Long-term Intervention with Pravastatin in Ischaemic Disease).

Lancet. 2002 Apr 20;359(9315):1379-87. Erratum in: Lancet 2002 Nov 2;360(9343):1430. PMID: 11978335 [PubMed - indexed for MEDLINE]Related articles

Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial.

Hunt D, Young P, Simes J, Hague W, Mann S, Owensby D, Lane G, Tonkin A.

Ann Intern Med. 2001 May 15;134(10):931-40.PMID: 11352694 [PubMed - indexed for MEDLINE]Related articlesFree article

Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?

Simes RJ, Marschner IC, Hunt D, Colquhoun D, Sullivan D, Stewart RA, Hague W, Keech A, Thompson P, White H, Shaw J, Tonkin A; LIPID Study Investigators.

Circulation. 2002 Mar 12;105(10):1162-9.PMID: 11889008 [PubMed - indexed for MEDLINE]Related articlesFree article

Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.

JAMA. 2002 Dec 18;288(23):2998-3007.PMID: 12479764 [PubMed - indexed for MEDLINE]Related articlesFree article

Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome.

Arca M.

Drugs. 2007;67 Suppl 1:43-54. Review.PMID: 17910520 [PubMed - indexed for MEDLINE]Related articles

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.

Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Protection Study Collaborative Group.

Lancet. 2003 Jun 14;361(9374):2005-16.PMID: 12814710 [PubMed - indexed for MEDLINE]Related articles

Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial.

Lewis SJ, Moye LA, Sacks FM, Johnstone DE, Timmis G, Mitchell J, Limacher M, Kell S, Glasser SP, Grant J, Davis BR, Pfeffer MA, Braunwald E.

Ann Intern Med. 1998 Nov 1;129(9):681-9.PMID: 9841599 [PubMed - indexed for MEDLINE]Related articlesFree article

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

Heart Protection Study Collaborative Group.

Lancet. 2002 Jul 6;360(9326):7-22.PMID: 12114036 [PubMed - indexed for MEDLINE]Related articles

Long-term risk stratification for survivors of acute coronary syndromes. Results from the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study. LIPID Study Investigators.

Marschner IC, Colquhoun D, Simes RJ, Glasziou P, Harris P, Singh BB, Friedlander D, White H, Thompson P, Tonkin A; Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study.

J Am Coll Cardiol. 2001 Jul;38(1):56-63.PMID: 11451296 [PubMed - indexed for MEDLINE]Related articles

A systematic review and economic evaluation of statins for the prevention of coronary events.

Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A, Yeo W, Payne N.

Health Technol Assess. 2007 Apr;11(14):1-160, iii-iv. Review.PMID: 17408535 [PubMed - indexed for MEDLINE]Related articlesFree article

Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.

[No authors listed]

JAMA. 2000 Apr 19;283(15):1967-75. Erratum in: JAMA 2002 Dec 18;288(23):2976. PMID: 10789664 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.

Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesäniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M; FIELD study investigators.

Lancet. 2005 Nov 26;366(9500):1849-61. Erratum in: Lancet. 2006 Oct 21;368(9545):1415. Lancet. 2006 Oct 21;368(9545):1420. PMID: 16310551 [PubMed - indexed for MEDLINE]Related articles

Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study.

Haffner SM, Alexander CM, Cook TJ, Boccuzzi SJ, Musliner TA, Pedersen TR, Kjekshus J, Pyörälä K.

Arch Intern Med. 1999 Dec 13-27;159(22):2661-7.PMID: 10597756 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of pravastatin in 3260 patients with unstable angina: results from the LIPID study.

Tonkin AM, Colquhoun D, Emberson J, Hague W, Keech A, Lane G, MacMahon S, Shaw J, Simes RJ, Thompson PL, White HD, Hunt D.

Lancet. 2000 Dec 2;356(9245):1871-5.PMID: 11130382 [PubMed - indexed for MEDLINE]Related articles

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH; CARDS investigators.

Lancet. 2004 Aug 21-27;364(9435):685-96.PMID: 15325833 [PubMed - indexed for MEDLINE]Related articles

Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).

Sever PS, Poulter NR, Dahlöf B, Wedel H, Collins R, Beevers G, Caulfield M, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J.

Diabetes Care. 2005 May;28(5):1151-7.PMID: 15855581 [PubMed - indexed for MEDLINE]Related articlesFree article